- Home
- » Tags
- » Pexidartinib
Top View
- Pexidartinib (Turalio™) EOCCO POLICY
- Go Or No Go? Abbvie, Roche and Kala Await Key Decisions
- Multi-Discipline Review
- Drug-Induced Liver Injury (DILI): Current Status and Future Directions for Drug Development and the Post-Market Setting
- November 18 - 21, 2020
- Stembook 2018.Pdf
- Innovations and Patent Trends in the Development of USFDA Approved Protein Kinase Inhibitors in the Last Two Decades
- Evaluation of Pharmacokinetics, Drug-Likeness, and Medicinal
- Press Release
- FDA Updates Highlighting the Latest Cancer Treatments
- Perioperative Medication Management - Adult/Pediatric - Inpatient/Ambulatory Clinical Practice Guideline
- New Frontiers in Therapy of Peripheral Nerve Sheath Tumors In
- Latest Advances in Targeting the Tumor
- Pharmacy Medical Necessity Guidelines: Oral Cancer Medications Effective: August 16, 2021
- Oncology Oral, Other Therapeutic Class Review
- Tenncare Autoexempt List September 1, 2021 This Is a Current List of the Drugs and Supplies That Do Not Count Toward an Enrollee’S Monthly Drug Limit
- Consolidated Financial Results
- ATC/DDD Classification (Final)
- Therapeutic Advances in Oncology
- Pexidartinib (PLX3397)
- Drug Information Center Highlights of FDA Activities – 8/1/19
- Oncology Pipeline
- Study Protocol and Statistical Analysis Plan
- Table 1. Summary of Kinase Inhibitors Approved by the FDA for Treatment
- Medicare Model Guidelines Draft V8.0 1 of 97
- Oncology Medications Policy (1403)
- Long‐Term Outcomes of Pexidartinib in Tenosynovial Giant Cell Tumors
- Oncology Agents Policy #: Rx.01.67
- Ventegra Overview
- RTK Inhibitors in Melanoma: from Bench to Bedside
- For Immediate Release Company Name: DAIICHI SANKYO COMPANY, LIMITED Representative: Joji Nakayama, Representative Director, Pres
- HUTCHMED (China) Limited Supplemental and Updated Disclosures
- October 2017 a View Into Upcoming Specialty and Traditional Drugs TABLE of CONTENTS
- Oncology Center of Excellence 2019 Annual Report
- WO 2017/137958 Al 17 August 2017 (17.08.2017) P O P C T
- Tyrosine Kinase Inhibitors - Oral
- Kristen N. Ganjoo, MD Stanford University Medical Center 875 Blake Wilbur Drive, CC2228 Stanford, CA 94305-5821 (650)498-6000
- Emetic Risk of Single Intravenous Antineoplastic Agents in Adults
- Latest Advances in Targeting the Tumor
- Colony-Stimulating Factor 1 Receptor (CSF1R) Inhibitors in Cancer Therapy Michael A
- Daiichi Sankyo Cancer Enterprise Delivering on Our Development Promises Investors Analysts Presentation from ASCO Chicago, IL June 1St, 2018
- Pharmacy Medical Necessity Guidelines: Oral Cancer Medications Effective: October 1, 2021
- Turalio (Pexidartinib)
- January 2018 a View Into Upcoming Specialty and Traditional Drugs TABLE of CONTENTS
- Pharmacological Approaches in Neurofibromatosis Type 1
- Gastrointestinal Stromal Tumors (Gists): Novel Therapeutic Strategies with Immunotherapy and Small Molecules
- 16722836) Imatinib (Pubmed CID: 123596) in the Treatment of Urothelial Bladder Cancers
- Press Release
- Evolving Therapeutic Strategies Maintain Clinical Momentum in Melanoma Jane De Lartigue, Phd
- Ds-8201 Ds-1062 U3-1402
- Overview of 2019 CDER Drug Approvals in Hematology/Oncology
- Supplementary Table 2
- Ripretinib and MEK Inhibitors Synergize to Induce Apoptosis in Preclinical Models of GIST And
- Pexidartinib (TURALIO™): the First FDA-Indicated Systemic Treatment for Tenosynovial Giant Cell Tumor
- Discovery of Vimseltinib (DCC -3014), a Highly Selective Switch
- Tropomyosin Receptor Kinase Inhibitors in the Management Of
- Global Offering
- Overcoming Resistance to FLT3 Inhibitors in the Treatment of FLT3-Mutated AML